A Randomized Study Comparing the Effects of PF708 and Forteo in Patients With Osteoporosis
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Teriparatide (Primary)
- Indications Osteoporosis
- Focus Pharmacodynamics; Registrational
- Sponsors Pfenex
- 09 Aug 2017 According to a Pfenex media release, the company expects to submit the new drug application (NDA) in the third quarter of 2018 to the FDA.
- 09 Aug 2017 According to a Pfenex media release, the enrollment of the study is approaching completion and interim pharmacokinetic data from this study is expected in the second half of 2017.The immunogenicity data is expected in the first half of 2018.
- 08 May 2017 According to a Pfenex media release, the company expects to complete the enrollment in this study in the second half of 2017.